BridgeBio Pharma

Yahoo Finance • 8 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025,... Full story

Yahoo Finance • 19 days ago

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysis This profound treatment effect, due to the n... Full story

Yahoo Finance • 21 days ago

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. Is the Biot... Full story

Yahoo Finance • 26 days ago

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes... Full story

Yahoo Finance • last month

BridgeBio Announces CFO Succession

PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has b... Full story

Yahoo Finance • 2 months ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced at 1.75% interest rate and 45% conversion premium PALO ALTO, Calif., Feb. 25, 2025... Full story

Yahoo Finance • 2 months ago

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends de... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the F... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial... Full story

Yahoo Finance • 2 months ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date In as few as 3 months, the time to first event (all-cause... Full story

Yahoo Finance • 2 months ago

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts.In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other healthcare stocks. McKinsey repo... Full story

Yahoo Finance • 3 months ago

Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other unstoppable stocks to buy in 2025. As per the recent ear... Full story

Yahoo Finance • 11 months ago

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. - Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and c... Full story

Yahoo Finance • last year

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. - In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demon... Full story

Yahoo Finance • last year

BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

March 4 (Reuters) - BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday. The experimental drug, acoramidis, is being developed as an oral... Full story

Yahoo Finance • last year

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

BridgeBio Pharma, Inc. - BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according to a tiere... Full story

Yahoo Finance • last year

14 Best Medical Stocks To Invest In According to Hedge Funds

In this piece, we will take a look at the 14 best medical stocks to invest in according to hedge funds. If you want to skip our overview of the medical and healthcare industry, then you can take a look at the 5 Best Medical Stocks To Inves... Full story

Yahoo Finance • last year

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

BridgeBio Pharma, Inc. - The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue O... Full story

Yahoo Finance • last year

16 Best Mid Cap Growth Stocks To Buy Now

In this article, we will take a detailed look at the16Best Mid-Cap Growth Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Mid-Cap Growth Stocks To Buy Now. Investors are hopeful that small- and mid-cap stock... Full story

Yahoo Finance • last year

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

BridgeBio Pharma, Inc. The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct... Full story